Published in Cancer Weekly, May 16th, 2000
"Although RCC has been shown to respond to immunotherapy, RCC-specific rejection antigens and their corresponding cytotoxic T lymphocyte (CTL) epitopes have rarely been described," noted Johannes Vieweg and colleagues from Duke University Medical Center, North Carolina. "The use of dendritic cells (DC) transfected with antigen encoded in tumor RNA may allow specific immunotherapy even in cancers in which relevant rejection antigens have, so far, not been identified."
Vieweg et al. presented data from their study at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.